CompletedPhase 2NCT00002571
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Lode J. Swinnen, MD, MDLoyola University
- Intervention
- bleomycin sulfate(biological)
- Enrollment
- 52 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1994 – 2011
Study locations (30)
- MBCCOP - University of South Alabama, Mobile, Alabama, United States
- CCOP - Greater Phoenix, Phoenix, Arizona, United States
- Veterans Affairs Medical Center - Phoenix (Hayden), Phoenix, Arizona, United States
- Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States
- Arizona Cancer Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States
- Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Beckman Research Institute, City of Hope, Los Angeles, California, United States
- Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
- CCOP - Bay Area Tumor Institute, Oakland, California, United States
- Chao Family Comprehensive Cancer Center, Orange, California, United States
- University of California Davis Medical Center, Sacramento, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002571 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital